Home › FDA Approves Perjeta For Neoadjuvant Breast Cancer Treatment
 

Keywords :   


FDA Approves Perjeta For Neoadjuvant Breast Cancer Treatment

2013-10-02 06:33:29| drugdiscoveryonline News Articles

The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer

Tags: treatment cancer breast breast cancer

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
24.11STEINBACH40
24.11 Sepua Crue F-170
24.11 SECRET
24.11CRAwith
24.1111/15)&&
24.11 8
24.11
24.11F2023 23
More »